Research Insight
EU study shows once-daily lisdexamfetamine dimesylate (LDX) effective for...
Shire plc, the global specialty biopharmaceutical company, today presented positive top line results of the first European phase III study of once-daily lisdexamfetamine dimesylate (LDX)...
Research Insight
NIH researchers show how anti-HIV drug acts to block...
An anti-HIV drug also discovered to stop the spread of the genital herpes virus does so by disabling a key DNA enzyme of the herpes...
Research Insight
New Study Shows Cialis® Significantly Improved Study Endpoints in...
Eli Lilly and Company announced that a pivotal Phase III study of Cialis® (tadalafil) tablets 5 mg for once daily use met its co-primary endpoints,...
Research Insight
Hybrigenics’ inecalcitol inhibits the growth of human hormone-dependent prostate...
Hybrigenics (ALHYG), a bio-pharmaceutical company listed on Alternext in Paris, with a focus on research and development of new treatments of proliferative diseases, announces...
Research Insight
New Study Released Showed Patients With Deadly Form of...
Eli Lilly and Company announced that PARAMOUNT, its Phase III study evaluating ALIMTA® (pemetrexed for injection) in the continuation maintenance setting, met its primary endpoint...
Research Insight
King’s College London Prostate cancer treatment study shows percentage...
A study co-led by researchers at King’s College London shows that the percentage of men who had a radical prostatectomy (removal of the prostate and...
Research Insight
Abbott and Enanta Present Positive 12-Week Results and 3-Day...
Abbott and Enanta Pharmaceuticals today announced 12-week results from a Phase 2 study of ABT-450/r, an investigational, oral protease inhibitor being developed for the...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.